301221-79-4|tert-Butyl 4-(2-bromoacetyl)piperidine-1-carboxylate| Ambeed

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Structure of 301221-79-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 301221-79-4 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 301221-79-4 ]

CAS No. :	301221-79-4
Formula :	C₁₂H₂₀BrNO₃
M.W :	306.20
SMILES Code :	O=C(N1CCC(C(CBr)=O)CC1)OC(C)(C)C
MDL No. :	MFCD11975555
InChI Key :	HYRSGTXIVIMOOX-UHFFFAOYSA-N
Pubchem ID :	18187487

Safety of [ 301221-79-4 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H302-H314
Precautionary Statements:	P260-P264-P270-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P310-P363-P405-P501
Class:	8
UN#:	1759
Packing Group:	Ⅲ

Computational Chemistry of [ 301221-79-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	17
Num. arom. heavy atoms	0
Fraction Csp3	0.83
Num. rotatable bonds	5
Num. H-bond acceptors	3.0
Num. H-bond donors	0.0
Molar Refractivity	74.28
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	46.61 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.8
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.08
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.22
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.73
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.04
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.17

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.72
Solubility	0.585 mg/ml ; 0.00191 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.69
Solubility	0.627 mg/ml ; 0.00205 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.47
Solubility	1.05 mg/ml ; 0.00342 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.69 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.53

Application In Synthesis of [ 301221-79-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 301221-79-4 ]

[ 301221-79-4 ] Synthesis Path-Downstream 1~35

1
[ 78622-21-6 ]
[ 301221-79-4 ]
[ 301221-80-7 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

2
[ 206989-61-9 ]
[ 301221-79-4 ]

Yield	Reaction Conditions	Operation in experiment
96%		INTERMEDIATE B6 tert-Butyl 4-(bromoacetyl)piperidine-l-carboxylate To a cooled (-78 0C) suspension of tert-butyi 4-acetylpiperidine-l-carboxylate (Intermediate B5; 2.87 g, 12.6 mmol) in THF (30 mL) was added 1 M lithium bis(trimethylsilyl)amide in THF (13.3 mL) over 20 min. The mixture was stirred for 1 h before the addition of trimethylsilyl chloride (1.74 mL, 13.7 mmol). After stirring at 0 0C for 30 min, the solution was cooled to -78 0C and bromine (0.645 mL, 12.6 mmol) was added. The mixture was allowed to reach r.t. and then poured into a solution of 10percent Na2S2O3 (20 mL) and saturated NH4Cl (20 mL). Extraction with EtOAc (2 x 80 mL) gave the title compound. Yield 3.69 g (96percent).
		To a cooled (-78 °C) solution of 2.0 M LDA (in HEPTANE/THF/BENZENE, 13.7 mL, 27.3 mmol) in 100 mL THF was added dropwise over 40 min a solution of the methyl ketone prepared as described in Step B (5.17 g, 22.8 mmol) in 40 mL THF. After an additional 25 min, chlorotrimethylsilane (5.79 ML, 45.6 mmol) was added dropwise over 10 minutes. After stirring the for 1 h, the reaction mixture was poured into 300 mL of saturated NAHC03 solution and the resulting mixture was extracted twice with 200 mL of ether. The combined ethereal layers were washed with brine, dried over anhydrous MGS04, filtered, and concentrated to give 7.35 g of TMS-enol ether, which was then redissolved in 120 ML THF, cooled to 0 °C, and treated with sodium bicarbonate (2.87 g, 34.2 mmol), followed by N-BROMOSUCCINIMIDE (4.06 g, 22.8 mmol). The reaction mixture was warmed to rt and stirred for 1 h and 10 min, at which point, it was poured into 200 ML of saturated NAHC03 solution. The resulting mixture was extracted twice with 200 mL of ether and the combined ethereal layers were washed with saturated NAHC03 solution and brine, dried over anhydrous MGS04, filtered, and concentrated to give 7.62 g of crude product which was used without further purification.
		Intermediate F: Preparation of tert-butyl 4- 2-bromoacetyl)piperidine-l-carboxylate To a solution of tert-butyl 4-acetylpiperidine-l-carboxylate (2.0 g, 8.8 mmol) in THF (50 mL) was added LHMDS (10.5 mL, 10.5 mmol) at -78 °C. The reaction was stirred at that temperature for 1 h. Then trimethyl chlorosilane (1.45 mL, 11.4 mmol) was added. The mixture was warmed to 0 °C and stirred at that room temperature for 30 min, then cooled to -78 °C again. Br2 (0.45 mL, 8.8 mmol) was added. The reaction mixture was warmed to room temperature and stirred at that room temperature for 30 min. Saturated Na2S03 aqueous solution (30 mL) was added to the reaction vessel and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine, dried over anhydrous Na2S04, filtered and concentrated in vacuo. The resulting oil (3.2 g) was directly used for the next step without further purification. LCMS [M+H]+ =306.1.

References: [1]Patent: WO2009/150144,2009,A1 .Location in patent: Page/Page column 139.
[2]Tetrahedron Letters,2012,vol. 53,p. 852 - 853.
[3]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.
[4]Patent: WO2004/41279,2004,A1 .Location in patent: Page/Page column 70.
[5]Patent: WO2015/88565,2015,A1 .Location in patent: Paragraph 00214.
[6]Patent: WO2008/42925,2008,A1 .

3
4-methoxyaminoacetyl-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]
[ 301221-79-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

4
[ 504-29-0 ]
[ 301221-79-4 ]
4-imidazo[1,2-a]pyridin-2-yl-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

5
[ 109-12-6 ]
[ 301221-79-4 ]
4-imidazo[1,2-a]pyrimidin-2-yl-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

6
[ 5049-61-6 ]
[ 301221-79-4 ]
4-imidazo[1,2-a]pyrazin-2-yl-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

7
[ 84358-13-4 ]
[ 301221-79-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.
[2]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.
[3]Patent: WO2009/150144,2009,A1 .
[4]Patent: WO2008/42925,2008,A1 .

8
[ 301221-79-4 ]
2-piperidin-4-yl-imidazo[1,2-a]pyridine; compound with trifluoro-acetic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

9
[ 301221-79-4 ]
2-piperidin-4-yl-imidazo[1,2-a]pyrazine; compound with trifluoro-acetic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

10
[ 301221-79-4 ]
2-piperidin-4-yl-imidazo[1,2-a]pyrimidine; compound with trifluoro-acetic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2129 - 2134.

11
[ 139290-70-3 ]
[ 301221-79-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.
[2]Patent: WO2009/150144,2009,A1 .
[3]Patent: WO2008/42925,2008,A1 .

12
[ 301221-79-4 ]
4-(2-benzyl-3H-imidazol-4-yl)-piperidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

13
[ 301221-79-4 ]
4-(2-benzyl-5-chloro-3H-imidazol-4-yl)-piperidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

14
[ 301221-79-4 ]
4-(2-benzyl-5-ethyl-3H-imidazol-4-yl)-piperidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

15
[ 301221-79-4 ]
[ 301221-81-8 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

16
[ 301221-79-4 ]
[ 301221-85-2 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

17
[ 301221-79-4 ]
[ 301221-87-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

18
[ 301221-79-4 ]
[ 301221-83-0 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

19
[ 301221-79-4 ]
[ 301221-84-1 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 3419 - 3424.

20
[ 17356-08-0 ]
[ 301221-79-4 ]
[ 690261-84-8 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In ethanol; at 60℃; for 8h;	The bromomethylketone prepared as described in Steps A through C of the synthesis of Intermediate 14 (1.68 g, 5.47 mmol) was combined with thiourea (625 mg, 8.21 mmol) and potassium carbonate (1.51 g, 10.9 mmol) in ethanol and the resulting mixture was stirred at 60 °C for 8 h. The reaction mixture was then concentrated and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted again with ethyl acetate and the combined organic layers were washed with brine, dried over anhydrous MGS04, filtered, and concentrated to give 1.42 g of crude aminothiazole product.
	In isopropyl alcohol; at 20℃; for 1h;	a) Preparation of 4-(2-amino-thiazol-4-yl)-piperidine-1 -carboxylic acid tert-butyl ester A suspension of thiourea (7.7g, 0.1 mol) in 520 ml of isopropanol is slowly added to a solution of <strong>[301221-79-4]4-(2-bromo-acetyl)-piperidine-1-carboxylic acid tert-butyl ester</strong> (14.3 g, 50.5 mmol) in 260 ml of isopropanol. The reaction mixture is stirred for 1 h at room temperature and subsequently poured slowly into 500 ml of a 1 N aqueous sodium carbonate solution, keeping the temperature between 20 and 30 °C by ice cooling. After separation of the phases, the aqueous layer is extracted twice with ethyl acetate. The combined organic phase is washed with brine and with water, dried over sodium sulfate and evaporated to dryness, delivering directly 4-(2-amino-thiazol-4-yl)-piperidine-1 -carboxylic acid tert-butyl ester as beige cristals. 1H-NMR (400 MHz, CDCI3): delta = 1.46 (s, 9H), 1.53 (dd, 2H), 1 .95 (dd, 2H), 2.61 - 2.82 (m, 3H), 4.14 (bs, 2H), 4.88 - 4.93 (m, 2H), 6.09 (s, 1 H). MS: m/z = 284 (M+1 ).
	In isopropyl alcohol; at 20℃; for 1h;	a) Preparation of 4-(2-amino-thiazol-4-yl)piperidine-1-carboxylic acid tert-butyl ester A suspension of thiourea (7.7 g, 0.1 mol) in 520 ml of isopropanol is slowly added to a solution of <strong>[301221-79-4]4-(2-bromo-acetyl)-piperidine-1-carboxylic acid tert-butyl ester</strong> (14.3 g, 50.5 mmol) in 260 ml of isopropanol. The reaction mixture is stirred for 1 h at room temperature and subsequently poured slowly into 500 ml of a 1 N aqueous sodium carbonate solution, keeping the temperature between 20 and 30° C. by ice cooling. After separation of the phases, the aqueous layer is extracted twice with ethyl acetate. The combined organic phase is washed with brine and with water, dried over sodium sulfate and evaporated to dryness, delivering directly 4-(2-amino-thiazol-4-yl)piperidine-1-carboxylic acid tert-butyl ester as beige crystals. 1H-NMR (400 MHz, CDCl3): delta=1.46 (s, 9H), 1.53 (dd, 2H), 1.95 (dd, 2H), 2.61-2.82 (m, 3H), 4.14 (bs, 2H), 4.88-4.93 (m, 2H), 6.09 (s, 1H). MS: m/z=284 (M+1).

References: [1]Patent: WO2004/41777,2004,A2 .Location in patent: Page 56-57.
[2]Patent: WO2013/56915,2013,A1 .Location in patent: Page/Page column 34.
[3]Patent: US2014/228372,2014,A1 .Location in patent: Paragraph 0172.

21
[ 115-08-2 ]
[ 301221-79-4 ]
[ 690261-82-6 ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; at 60℃; for 96h;	The bromomethylketone prepared as described in Step C (1.48 g, 4.83 mmol) was combined with thioformamide (295 mg, 4.83 mmol) in 10 mL of THF. The reaction mixture was warmed to 60 °C and stirred for 4 days. The reaction mixture was then diluted with ethyl acetate and washed with water, then brine, dried over anhydrous MGS04, filtered, and concentrated. Purification by MPLC (silica, 60percent ethyl acetate/hexane) afforded 627 mg OF THIAZOLE PRODUCT. 1H NMR (400 MHz, CDCl3) : 8 8.75 (d, J = 2.0 Hz, 1H), 6.93 (d, J = 2.4 Hz, 1H), 4.19 (br s, 2H), 2.96 (m, 1H), 2.84 (br m, 2H), 2.03 (m, 2H), 1.62 (m, 2H), 1.44 (s, 9H).
	In tetrahydrofuran; at 60℃; for 96h;	The bromomethylketone prepared as described in Step C (1.48 g, 4.83 mmol) was combined with thioformamide (295 mg, 4.83 mmol) in 10 mL of THF. The reaction mixture was warmed to 60 °C and stirred for 4 days. The reaction mixture was then diluted with ethyl acetate and washed with water, then brine, dried over anhydrous MgS04, filtered, and concentrated. Purification by MPLC (silica, 60percent ethyl acetate/hexane) afforded 627 mg of thiazole PRODUCT. 1H NMR (400 MHz, CDC13) : 8 8.75 (d, J = 2.0 Hz, 1H), 6.93 (d, J = 2.4 Hz, 1H), 4.19 (br s, 2H), 2.96 (m, 1H), 2.84 (BR M, 2H), 2.03 (m, 2H), 1.62 (m, 2H), 1.44 (s, 9H).

References: [1]Patent: WO2004/41777,2004,A2 .Location in patent: Page 55-56.
[2]Patent: WO2004/41279,2004,A1 .Location in patent: Page/Page column 70.

22
C₁₅H₂₉NO₃Si [ No CAS ]
[ 301221-79-4 ]

Yield	Reaction Conditions	Operation in experiment
	With N-Bromosuccinimide; sodium hydrogencarbonate; In tetrahydrofuran; at 0 - 20℃; for 1.16667h;	To a cooled (-78 °C) solution of 2.0 M LDA (in HEPTANE/THF/BENZENE, 13.7 mL, 27.3 mmol) in 100 mL THF was added dropwise over 40 min a solution of the methyl ketone prepared as described in Step B (5.17 g, 22. 8 mmol) in 40 ML THF. After an additional 25 min, chlorotrimethylsilane (5.79 ML, 45.6 mmol) was added dropwise over 10 minutes. After stirring the for 1 h, the reaction mixture was poured into 300 mL of saturated NAHCO3 solution and the resulting mixture was extracted twice with 200 mL of ether. The combined ethereal layers were washed with brine, dried over anhydrous MGS04, filtered, and concentrated to give 7.35 g of TMS-enol ether, which was then redissolved in 120 ML THF, cooled to 0 °C, and treated with sodium bicarbonate (2.87 g, 34.2 mmol), followed by N-bromosuccinimide (4.06 g, 22.8 mmol). The reaction mixture was warmed to rt and stirred for 1 h and 10 min, at which point, it was poured into 200 ML of saturated NAHCO3 solution. The resulting mixture was extracted twice with 200 mL of ether and the combined ethereal layers were washed with saturated NAHCO3 solution and brine, dried over anhydrous MgS04, filtered, and concentrated to give 7.62 g of crude product which was used without further purification.

References: [1]Patent: WO2004/41777,2004,A2 .Location in patent: Page 55.

23
[ 3473-63-0 ]
[ 301221-79-4 ]
[ 152241-38-8 ]

Yield	Reaction Conditions	Operation in experiment
	With ammonia; at 40℃; under 10032.9 Torr; for 20h;	The bromomethylketone prepared as described in Steps A-C of the synthesis of Intermediate 10 (2.02 g, 6.60 mmol) was combined with FORMAMIDINE acetate (1.37 g, 13.2 mmol) in-130 mL of NH3 (1) and heated in an autoclave at 40 °C and 194 psi for 20 h. The NH3 was allowed to evaporate, the residue was dissolved in DCM and filtered. The filtrate was concentrated. Purification by flash chromatography (silica, 10percent of 1: 9 NH4OH/METHANOL in DCM) afforded 649 mg of the imidazole product. APOS;H NMR (400 MHz, CD30D) : 8 7.56 (d, J = 1.2 Hz, 1H), 6.74 (d, J = 1. 2 Hz, 1H), 4.13 (br s, 2H), 2.82 (m, 2H), 2.74 (m, 1H), 1.97 (m, 2H), 1.54 (m, 2H), 1.44 (s, 9H).

References: [1]Patent: WO2004/41279,2004,A1 .Location in patent: Page/Page column 71.

24
silyl enolether [ No CAS ]
[ 206989-61-9 ]
[ 301221-79-4 ]

Yield	Reaction Conditions	Operation in experiment
	With N-Bromosuccinimide; n-butyllithium; triethylamine; diisopropylamine; In tetrahydrofuran; hexane; methyloxirane;	Step A 4-Bromoacetyl-1-t-butoxycarbonyl-piperidine To a freshly prepared solution of LDA (from diisopropylamine (0.61 g, 6.0 mmol) and n-BuLi (2.2 ml, 2.5 M soln. in hexane) in 10 ml THF at -78° C. was added a solution of 4-acetyl-1-t-butoxycarbonyl-piperidine (1.0 g, 4.7 mmol) in 2.0 ml THF and the resultant mixture was stirred for 20 min. A mixture of TMSCl and triethylamine (1.37 ml, 10.8 mmol and 2.16 ml, 15.5 mmol) was added and the reaction mixture was gradually warmed to RT and stirred for an additional 1 hr. All the volatiles were removed and the crude silyl enolether was dissolved in 10 mL of THF and the mixture was cooled to 0° C. To this mixture was added in succession propylene oxide (1.0 ml) and NBS (1.0 g) and the mixture was stirred for 15 min, quenched with saturated NaHCO3 solution followed by extraction with CH2Cl2. The CH2Cl2 layer was washed with brine, dried, evaporated and purified by silica column chromatography. Elution with methylene chloride and ether (19:1) gave the title compound (1.11 g) as an yellow solid. 1H-NMR (500MHz, CDCl3): delta 4.16 (s, 2H), 4.12 (m, 2H), 2.79-2.84 (m, 3H), 1.5-2. (m, 4H), 1.47 (s, 9H).

References: [1]Patent: US6248755,2001,B1 .

25
[ 187669-60-9 ]
[ 301221-79-4 ]
[ 918884-07-8 ]

Yield	Reaction Conditions	Operation in experiment
65%	With potassium carbonate; In acetonitrile; for 4h;Heating / reflux;	Example 67; 4-{2-[4-(4-Methanesulfonylphenyl)piperazin-l-yl]acetyl}piperidine-l- carboxylic acid tert-butyl ester; To a solution of l-(4-methanesulfonylphenyl)piperazine (0.055g, 0.23mmol) in MeCN (2mL) was added 4-(2-bromoacetyl)piperidine-l-carboxylic acid tert-butyl ester (0.07g, 0.23mmol) and K2CO3 (0.035g, 0.25mmol). The mixture was heated at reflux for 4h then allowed to cool. EtOAc (2OmL) was added and the organic phase washed with water, brine, dried (MgSO4) and the solvent removed in vacuo. The crude mixture was purified by flash chromatography with EtOAc as eluent to afford the title compound (0.07g, 65percent): RT = 2.45 min; m/z (ES+) = 466.4 [M+ H]+

References: [1]Patent: WO2007/3964,2007,A1 .Location in patent: Page/Page column 45.

26
[ 953045-84-6 ]
[ 301221-79-4 ]
[ 953045-85-7 ]

Yield	Reaction Conditions	Operation in experiment
82.0%	With triethylamine; In ethanol; at 70℃; for 2h;	A 50 mL flask was charged with l-(3-(2-bromo-4-fluorophenoxy)-5-(3-methoxyphenylthio)pyridin-2-yl)thiourea (1.5 g, 3.12 mmol), triethylamine (0.740 mL, 5.31 mmol), tert-butyl 4-(2-bromoacetyl)piperidine-l-carboxylate (1.15 g, 3.75 mmol), and EtOH (25 mL). The reaction was heated to 70 °C for 2 hours. The reaction was partitioned between EtOAc and water. The organic layer was dried with sodium sulfate, filtered and concentrated. The residue was purified on silica (10percent EtOAc in hexanes) to afford tert-butyl 4-(2-(3-(2-bromo-4-fluorophenoxy)-5-(3-methoxyphenylthio)pyridin-2-ylamino)thiazol-4- yl)piperidine-l-carboxylate (1.76 g, 82.0percent yield).

References: [1]Patent: WO2008/118718,2008,A2 .Location in patent: Page/Page column 70.

27
[ 953045-99-3 ]
[ 301221-79-4 ]
5-bromo-3-phenoxy-N-(4-(piperidin-4-yl)thiazol-2-yl)pyridin-2-amine dihydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83.6%	With triethylamine; In tetrahydrofuran; at 60℃; for 3h;	A 25 mL flask was charged with l-(5-bromo-3-phenoxypyridin-2- yl)thiourea (500 mg, 1.54 mmol), tert-butyl 4-(2-bromoacetyl)piperidine-l-carboxylate (661 mg, 2.16 mmol), triethylamine (0.376 mL, 2.70 mmol), and THF (10 mL). The reaction was heated to 60 °C for 3 hours. The reaction was cooled to ambient temperature and poured into water and extracted with EtOAc. The organic layer was dried with sodium sulfate, filtered and concentrated in vacuo. The residue was purified on silica (30percent EtOAc in hexanes). The isolated material was dissolved in CH2Cl2MeOH (1:1) and 4N HCl in dioxane added. The reaction was concentrated to afford 5-bromo-3-phenoxy-N-(4-(piperidin-4-yl)thiazol-2- yl)pyridin-2-amine dihydrochloride (650 mg, 83.6percent yield) as a pale yellow solid.

References: [1]Patent: WO2008/118718,2008,A2 .Location in patent: Page/Page column 44.

29
[ 1043022-99-6 ]
[ 301221-79-4 ]
[ 1043022-82-7 ]

Yield	Reaction Conditions	Operation in experiment
94%	With triethylamine; In ethanol; at 70℃;	Step G: Preparation of tert-butyl 4-(2-(5-bromo-4-(2-methylpyridin-3- yloxy)pyridin-2-ylamino)thiazol-4-vDpiperidine- 1 -carboxylate : l-(5-Bromo-4-(2- methylpyridin-3-yloxy)pyridin-2-yl)thiourea (1.48 g, 4.4 mmol), tert-butyl 4-(2- bromoacetyl)piperidine-l -carboxylate (1.41 g, 4.60 mmol, prepared from \\-{tert- butoxycarbony)piperidine-4-carboxylic acid utilizing the procedure from Example 1 , steps A- C), and triethylamine (0.93 mL, 6.56 mmol) were diluted in ethanol (130 mL). The reaction was stirred at 70 0C overnight and then concentrated. Water was added and the solution was extracted with ethyl acetate, dried and concentrated to give the title compound (2.37 g, 94percent yield) as light yellow solid.

References: [1]Patent: WO2008/91770,2008,A1 .Location in patent: Page/Page column 42.

30
[ 1046793-70-7 ]
[ 301221-79-4 ]
[ 1046793-50-3 ]

Yield	Reaction Conditions	Operation in experiment
93%	In tetrahydrofuran; at 20℃; for 264h;	tert-butyl 4-(2-(5-bromo-l-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-3- yl)thiazol-4-yl)piperidine-l -carboxylate (IH-m); (Xlll-a) (lll-m)To a solution of (XIII-a) (3.60 g, 9.08 mmol) in THF (50 mL) was added tert- butyl 4-(2-bromoacetyl)piperidine-l -carboxylate (2) (3.03 g, 9.90 mmol; preparation described in Bioorg. Med. Chem. Lett. 2004, 14, 3419, ibid. 2005,15, 2729) and the reaction mixture stirred at r.t. for H d. Saturated aqueousNaHCO3 (100 mL) was then added, and the mixture extracted with AcOEt (2 x150 mL). The combined organic extracts were dried (MgSO4) and concentrated to afford (III-m) (6.02 g, -85percent pure, 8.48 mmol, 93percent) as a yellow solid, which was used without additional purification.

References: [1]Patent: WO2008/95943,2008,A1 .Location in patent: Page/Page column 171.

31
[ 235106-12-4 ]
[ 301221-79-4 ]
[ 1018325-99-9 ]

Yield	Reaction Conditions	Operation in experiment
82%		[00193] Step 4: A mixture of 4-chloro-5-methyl-3-(trifluoromethyl)-lH-pyrazole (0.784 g, 4.25 mmol), anhydrous potassium carbonate (1.354 g, 9.80 mmol) and anhydrous acetonitrile (50 mL) was stirred at RT for 15 min and then treated with a solution of tert-bvXyl 4-(2-bromoacetyl)piperidine-l-carboxylate (1.0 g, 3.27 mmol) in anhydrous acetonitrile (5 mL). The resulting mixture was stirred at RT overnight to give a bright yellow mixture, which was concentrated on a rotary evaporator. The resultant residue was partitioned between EtOAc (50 mL) and water (25 mL). The organic phase was washed with 1 M NaOH (3 x 20 mL), washed with brine, dried (MgSO4) and concentrated on a rotary evaporator to give a yellow foam (1.5 g). The yellow foam was purified by flash chromatography using a 40 g silica gel cartridge and gradient elution from 10: 1 Hex/EtOAc to 3: 1 Hex/EtOAc (product Rf = 0.25 with 3: 1 Hexane / EtOAc; TLC visualized with KMnO4). The fractions containing the product were pooled and concentrated on a rotary evaporator to give tert-bvAyl 4-(2- (4-chloro-5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl)acetyl)piperidine-l- carboxylate (1.1 g, 2.68 mmol, 82percent yield). 1H-NMR (400 MHz, CDCl3) delta ppm 4.99 (2 H, s), 4.09 - 4.20 (2 H, m), 2.79 (2 H, t, J=12.41 Hz), 2.56 - 2.64 (1 H, m), 2.15 (3 H, s), 1.85 (2 H, d, J=I 1.86 Hz), 1.55 - 1.65 (2 H, m), 1.41 - 1.47 (9 H, m).

References: [1]Patent: WO2008/42925,2008,A1 .Location in patent: Page/Page column 97.

32
C₁₅H₂₉NO₃Si [ No CAS ]
[ 301221-79-4 ]

Yield	Reaction Conditions	Operation in experiment
	With N-Bromosuccinimide; sodium hydrogencarbonate; In tetrahydrofuran; at 0 - 20℃; for 1.5h;	[00192] Step 3: A solution of diisopropylamine (5.19 mL, 36.4 mmol) in anhydrous THF (10 mL) was cooled to -78 0C and then treated with n-BuLi (22.77 mL of a 1.6 M solution in hexanes, 36.4 mmol). After stirring for 15 min, the mixture was treated dropwise with a solution of tert-bvAyl 4-acetylpiperidine-l-carboxylate (6.9 g, 30.4 mmol) in anhydrous THF (50 mL) over 30 min. The resulting mixture was stirred at -78 0C for 40 min, treated with TMS-Cl (6.98 mL, 54.6 mmol) over 15 min and stirred for an additional hour. After this time, the reaction mixture was poured into sat NaHCO3 (350 mL) and extracted with Et2O (250 mL). The extract was washed with brine, dried (MgSO4) and concentrated on a rotary evaporator. The resultant residue was dissolved in anhydrous THF (150 mL). The resultant solution was cooled to 0 0C and treated sequentially with sodium bicarbonate (3.32 g, 39.5 <n="98"/>mmol) and NBS (4.86 g, 27.3 mmol). The mixture was stirred at RT for 90 min and then partitioned between saturated NaHCO3 (250 mL) and Et2O (250 mL). The aqueous phase was extracted with Et2O (200 mL). The combined ethereal extracts were washed with saturated NaHCO3, washed with brine, dried (MgSO4) and concentrated on a rotary evaporator to give a brown oil (9.5 g). After storing the product at -40 0C for 5 days, a portion of the oily product started to crystallize. The material was triturated with hexanes (3 x 100 mL) and then with Et2O (200 mL). The Et2O solution was decanted from the brown insoluble oil and concentrated in vacuo to give tert-bupsilonXyl 4-(2-bromoacetyl)piperidine-l-carboxylate (7.5 g, 24.49 mmol, 81 percent yield) as a pale brown oil, which partly crystallized on standing at RT. 1H-NMR (400 MHz, CDCl3) delta ppm 4.03 - 4.15 (2 H, m), 3.93 (2 H, s), 2.86 (1 H, tt, J=I 1.34, 3.82 Hz), 2.72 - 2.81 (2 H, m), 1.82 (2 H, d, J=12.30 Hz), 1.50 - 1.60 (2 H, m), 1.34 - 1.46 (9 H, m).

References: [1]Patent: WO2008/42925,2008,A1 .Location in patent: Page/Page column 96-97.

33
[ 123-75-1 ]
[ 301221-79-4 ]
[ 635698-74-7 ]

Yield	Reaction Conditions	Operation in experiment
87%	With triethylamine; In tetrahydrofuran; at 20℃; for 24h;	<strong>[301221-79-4]Tert-butyl 4-(2-bromoacetyl)piperidinecarboxylate</strong> (0.85 g, 2.8 mmol) was dissolved in tetrahydrofuran (8.5 mL), and the solution was mixed with pyrrolidine (0.46 mL, 5.6 mmol) and triethylamine (0.78 mL, 5.6 mmol) with stirring at room temperature, followed by stirring for twenty-four hours. The reaction mixture was mixed with diluted hydrochloric acid (0.5 mol/L , 27 mL) and washed with ethyl acetate. The aqueous layer was adjusted to be basic with an aqueous potassium hydroxide solution added under ice-cooling and was extracted with ethyl acetate. The organic layer was washed with brine, was dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was dried under reduced pressure and thereby yielded tert-butyl 4-(2-pyrrolidin-1-ylacetyl)piperidinecarboxylate (0.72 g, 87percent). APCI-MS m/z: 297 [M + H]+1H NMR (CDCl3) delta (ppm): 1.30-1.95 (m, 18H), 2.45-2.90 (m, 6H), 3.42 (s, 2H), 4.00-4.21 (m, 2H)

References: [1]Patent: EP1552842,2005,A1 .Location in patent: Page/Page column 306.

34
[ 38191-34-3 ]
[ 301221-79-4 ]
[ 1200576-13-1 ]

Yield	Reaction Conditions	Operation in experiment
84%		INTERMEDIATE B7 foert-Butyl 4-(7-bromo-2H-l,4-benzoxazin-3-yl)piperidine-l-carboxylate To a stirred solution of 2-amino-5-bromophenol (Intermediate B3; 898 mg, 4.78 mmol) in DMF (10 mL) was added K2CO3 (660 mg, 4.78 mmol). After 45 min, a solution of tert- <n="141"/>butyl 4-(bromoacetyl)piperidine-l-carboxylate (Intermediate B6; 1.53 g, ca 5 mmol) in DMF (2 rnL) was added and the mixture was stirred at r.t. overnight. Water was added and the product was extracted with toluene. The organic phase was washed with water and brine, dried and evaporated to give 952 mg of crude title compound (used in Intermediate B8). The aqueous layer was extracted with CHCI3 and the organic layer was concentrated. The residue was purified by flash chromatography on silica using 1percent MeOH/CHCl3 as eluent to give an additional 628 mg of the title compound. Total yield 1.58 g (84percent). Analytical HPLC: purity 83percent (System A); LRESIMS (ESI+) m/z = 339/341 (M+FRBu)+.

References: [1]Patent: WO2009/150144,2009,A1 .Location in patent: Page/Page column 139-140.

35
[ 824-75-9 ]
[ 301221-79-4 ]
[ 1207747-34-9 ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide; at 145℃; for 16h;	INTERMEDIATE 344-[2-(4-Fluoropheny1H3-oxazol-4-yl]piperidineA solution of 4-fluorobenzamide (4.54 g, 32.7 mmol) and /-butyl 4-(bromoacetyl)-piperidine-1- carboxylate (5.0 g, 16.3 mmol) in DMF (40 mL) was heated at 145°C for 16 h. Upon completion of the reaction, the solution was allowed to cool to rt and concentrated to a dark oil. The oil was purified by reverse phase HPLC to afford the title compound (760 mg). LC/MS: m/e 247.08 (M+H).div..
	In N,N-dimethyl-formamide; at 145℃; for 16h;	A solution of 4-fluorobenzamide (4.54 g, 32.7 mmol) and t-butyl 4-(bromoacetyl)-piperidine-1-carboxylate (5.0 g, 16.3 mmol) in DMF (40 mL) was heated at 145'C for 16 h. Upon completion of the reaction, the solution was allowed to cool to rt and concentrated to a dark oil. The oil was purified by reverse phase HPLC to afford the title compound (760 mg). LC/MS: m/e 247.08 (M+14)+.

References: [1]Patent: WO2010/17079,2010,A1 .Location in patent: Page/Page column 65-66.
[2]Patent: US2011/21531,2011,A1 .Location in patent: Page/Page column 31.

Historical Records

Technical Information

• Acyl Group Substitution • Alkyl Halide Occurrence • Baeyer-Villiger Oxidation • Barbier Coupling Reaction • Baylis-Hillman Reaction • Bucherer-Bergs Reaction • Chan-Lam Coupling Reaction • Clemmensen Reduction • Complex Metal Hydride Reductions • Corey-Bakshi-Shibata (CBS) Reduction • Corey-Chaykovsky Reaction • Fischer Indole Synthesis • General Reactivity • Grignard Reaction • Henry Nitroaldol Reaction • Hiyama Cross-Coupling Reaction • Horner-Wadsworth-Emmons Reaction • Hydride Reductions • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Lawesson's Reagent • Leuckart-Wallach Reaction • McMurry Coupling • Meerwein-Ponndorf-Verley Reduction • Passerini Reaction • Paternò-Büchi Reaction • Petasis Reaction • Peterson Olefination • Pictet-Spengler Tetrahydroisoquinoline Synthesis • Preparation of Aldehydes and Ketones • Preparation of Amines • Prins Reaction • Reactions of Aldehydes and Ketones • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Dihalides • Reformatsky Reaction • Robinson Annulation • Schlosser Modification of the Wittig Reaction • Schmidt Reaction • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • Stille Coupling • Stobbe Condensation • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling • Tebbe Olefination • Ugi Reaction • Wittig Reaction • Wolff-Kishner Reduction

Related Functional Groups of
[ 301221-79-4 ]

Bromides

A201879 [169457-73-2]

tert-Butyl 4-(2-bromoethyl)piperidine-1-carboxylate

Similarity: 0.86

A238495 [158407-04-6]

tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate

Similarity: 0.85

A207023 [188869-05-8]

tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate

Similarity: 0.85

A410265 [193629-39-9]

N-Boc-3-(bromomethyl)piperidine

Similarity: 0.82

A135211 [958026-66-9]

tert-Butyl 3-(2-bromoethyl)pyrrolidine-1-carboxylate

Similarity: 0.82

Amides

A298596 [206989-61-9]

tert-Butyl 4-acetylpiperidine-1-carboxylate

Similarity: 0.88

A753306 [419571-73-6]

tert-Butyl 4-propionylpiperidine-1-carboxylate

Similarity: 0.88

A232914 [191805-29-5]

tert-Butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate

Similarity: 0.86

A180994 [873924-08-4]

tert-Butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate

Similarity: 0.86

A201879 [169457-73-2]

tert-Butyl 4-(2-bromoethyl)piperidine-1-carboxylate

Similarity: 0.86

Ketones

A298596 [206989-61-9]

tert-Butyl 4-acetylpiperidine-1-carboxylate

Similarity: 0.88

A232914 [191805-29-5]

tert-Butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate

Similarity: 0.86

A180994 [873924-08-4]

tert-Butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate

Similarity: 0.86

A133687 [858643-92-2]

tert-Butyl 3-acetylpiperidine-1-carboxylate

Similarity: 0.85

A230096 [117565-57-8]

tert-Butyl 3-ethyl-4-oxopiperidine-1-carboxylate

Similarity: 0.85

Related Parent Nucleus of
[ 301221-79-4 ]

Piperidines

A298596 [206989-61-9]

tert-Butyl 4-acetylpiperidine-1-carboxylate

Similarity: 0.88

A753306 [419571-73-6]

tert-Butyl 4-propionylpiperidine-1-carboxylate

Similarity: 0.88

A232914 [191805-29-5]

tert-Butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate

Similarity: 0.86

A180994 [873924-08-4]

tert-Butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate

Similarity: 0.86

A201879 [169457-73-2]

tert-Butyl 4-(2-bromoethyl)piperidine-1-carboxylate

Similarity: 0.86

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 301221-79-4

{[proInfo.proName]}

CAS No.: 301221-79-4

Alternative Products

Product Details of [ 301221-79-4 ]

Safety of [ 301221-79-4 ]

Computational Chemistry of [ 301221-79-4 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 301221-79-4 ]

[ 301221-79-4 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 301221-79-4 ]

Bromides

Amides

Ketones

Related Parent Nucleus of
[ 301221-79-4 ]

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

{[proInfo.proName]}

CAS No.: 301221-79-4

{[proInfo.proName]}

CAS No.: 301221-79-4

Alternative Products

Product Details of [ 301221-79-4 ]

Safety of [ 301221-79-4 ]

Computational Chemistry of [ 301221-79-4 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 301221-79-4 ]

[ 301221-79-4 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of [ 301221-79-4 ]

Bromides

Amides

Ketones

Related Parent Nucleus of [ 301221-79-4 ]

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Related Functional Groups of
[ 301221-79-4 ]

Related Parent Nucleus of
[ 301221-79-4 ]